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Sex Med 2Introduction: The prevalence of polycystic ovary syndrome (PCOS) is 10e15% in women of reproductive age.
Its characteristics are (i) clinical or biochemical hyperandrogenism, (ii) oligomenorrhea or amenorrhea, and (iii)
polycystic ovaries on ultrasound. PCOS is associated with lower quality of life, depression, anxiety, diabetes, and
cardiovascular disease. Treatment commonly entails oral contraceptive use to lower endogenous androgen levels.
Androgen levels and comorbidities may affect sexual function. Previous studies have addressed a limited range of
possible contributing factors. We will assess sexual function as well as genital and self-reported sexual arousal in a
laboratory setting in women with PCOS compared to an age-matched healthy control group. Modulation by
biopsychosocial factors mentioned will be studied.
Methods: This is a multicenter prospective case control study. The study population includes healthy women
with and without PCOS, aged 18e40 years, in a stable heterosexual relationship for at least 6 months. Power is
calculated at 67 participants in each group. Anticipating a drop out of 10%, 150 participants will be recruited.
Main outcome measures: The main outcomes measured are sexual function using the Female Sexual Function
Index, Sexual Desire Inventory, and Female Sexual Distress Scale-Revised; genital sexual arousal measured as
vaginal pulse amplitude; and self-reported sexual arousal in response to erotic stimuli in a laboratory setting. The
mediators that will be investigated include testosterone, free androgen levels, oral contraceptive use, sensitivity to
androgens (using CAG repeat length), body mass index, body image, mental health, and self-esteem.
Conclusion: Strengths of this study are the inclusion of a broad range of biopsychosocial outcome measures
including DNA analysis, a healthy control group, and standardized assessment of genital and self-reported sexual
arousal in a laboratory setting. With the design of this study we aim to provide an insight into which bio-
psychosocial factors associated with PCOS are related to sexual function, and how sexual function may be
affected by treatment. These new insights may help to improve clinical management of PCOS while improving
the quality of life. Pastoor H, Both S, Timman R, et al. Sexual Function in Women With Polycystic Ovary
Syndrome: Design of an Observational Prospective Multicenter Case Control Study. Sex Med
2020;XX:XXXeXXX.
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2 Pastoor et alBACKGROUND
Polycystic ovary syndrome (PCOS) is the most common
endocrine disease in women. Its prevalence is estimated to be
between 5% and 15%1 in women of reproductive age. Its
characteristics are (i) either clinical (hirsutism) or biochemical
hyperandrogenism (elevated androgen serum levels), (ii) oligo-
menorrhea or amenorrhea, and (iii) polycystic ovaries on ultra-
sound.2 Following the Rotterdam criteria, PCOS is diagnosed
when 2 out of 3 characteristics are present.2 Treatment of PCOS
is complex and varies depending on symptoms and whether there
is a desire to have children. In the latter group, the first-line
treatment in women who are overweight or obese is lifestyle
modification followed by ovulation induction. Lifestyle changes
contribute to optimizing success rates in establishing a pregnancy
and reducing complication rates by normalizing insulin resistance
and consequently androgen levels.3e6 In women who do not
want to become pregnant, treatment usually consists of oral
contraceptive pill (OCP) use and lifestyle changes if indicated.7
Both interventions aim at improving endocrine disturbances by
normalizing insulin resistance and androgen metabolism. Simi-
larly, OCPs increase SHBG levels and hence reduce free
androgen levels.
PCOS is a distressing disease with symptoms such as sub-
fertility, hirsutism, and acne.7e10 It is associated with obesity,
insulin resistance, and unfavorable lipid profiles.7,9 Also, PCOS
is associated with lower quality of life, depression, and anx-
iety.7,11e16 The most recently published evidence-based guide-
line on PCOS mentions reduced health-related quality of life
scores for women with PCOS compared to a control popula-
tion.17 Health-related quality of life is influenced by the clinical
features of PCOS (mainly hirsutism, menstruation, and fertility)
and affected by anxiety, poor body image, low self-esteem,
depressive symptoms, delayed diagnosis, and inadequate educa-
tion about PCOS. The guideline also reports a 3 times higher
prevalence of depression15,18e22 and a 5-fold increase in the
incidence of anxiety disorders15,18e24 in women with PCOS.
Also, body image seems to be impaired in women with PCOS
compared to a control population.25 Although there is conflict-
ing evidence, hirsutism,26e28 increased weight,27,28 and infer-
tility26 seem to affect body image negatively. A negative body
image is strongly associated with depression.27,29,30 Finally,
disordered eating, eating disorders (mainly bulimia nervosa), and
risk factors for eating disorders seem to be more prevalent in
women with PCOS.19,31e33 Psychosocial factors such as anxiety,
depression,34,35 poor body image,36 and eating disorders37 are
recognized as potential risk factors for sexual dysfunction and
impaired sexual satisfaction.
Data on sexual function in women with PCOS are limited. A
systematic review on PCOS and sexual function by our research
group compared 18 studies in a meta-analysis.38 Sexual
dysfunction appeared to be more prevalent in women with
PCOS than in the control group. Particularly, sexual arousal,
lubrication, orgasm, and satisfaction were compromised. Effectsizes were small for the first 3 aspects of sexual function; for
satisfaction the effect size was large. In addition, women with
PCOS have fewer sexual thoughts, report self-perceived impaired
attractiveness, and report more problems participating in social
meetings due to bodily appearance than women without PCOS.
Also, women with PCOS report a negative impact of excessive
body hair on sexual function. For these variables effect sizes were
large, with the exception of number of sexual thoughts which
showed a medium effect size. Although women with PCOS were
less satisfied with their sex life, having a satisfying sex life was as
important to them as it was for control women. In the studies
assessed in this meta-analysis, sexual function was mainly studied
using questionnaires. Sample sizes were too small to make sub-
group comparisons to determine associations between sexual
function and weight, hirsutism, mental health, body image,
menstrual cycle, endocrine features, or use of OCPs.
It is known that sexual function is influenced by bio-
logical,39e46 psychological,34e36,47e49 and social factors.50,51 As
mentioned, in women with PCOS all these factors might be
compromised,17 potentially leading to compromised sexual
function.
Sex steroid hormones, in particular estrogens and androgens,
play an important role in sexual function,52e56 although the
exact mechanisms by which these steroids exert their influence
are still unclear.52,55e59 Androgens are believed to sensitize the
brain and genitals to sexual stimuli.53,55,60 Estrogens seem to
improve sexual function indirectly by improving vaginal health
and mood.55,57 Reduced levels of estrogens and androgens are
associated with alterations in genital tissue structure and inner-
vation, as well as with response to physiological modulators like
neuropeptides and neurotransmitters.61 Furthermore, estrogen
and androgen deficiencies are associated with reduced expression
of sex steroid receptors and most importantly with attenuated
genital blood flow and lubrication in response to pelvic nerve
stimulation.61
An important feature of PCOS is the alteration in sex steroid
hormones. In PCOS androgen levels are often elevated, leading
to biochemical and/or clinical hyperandrogenism. However,
women with PCOS do not report a higher level of sexual desire
compared to women without PCOS.38 In general, the relation-
ship between androgen levels and sexual desire in women is
inconclusive.57 Partly, this may be due to the fact that many
studies have assumed that androgens and sexual outcomes are
linearly and cross-sectionally related across the total serum
testosterone or free testosterone range. It is possible though that,
as in men,62,63 androgen-related sexual problems in women
should only be expected when androgen levels are below a certain
hypophysiological threshold. Even less is known about sexual
function in women who have androgen levels at the high end of
the normal range or who have hyperphysiological androgen
levels. In women, findings of a number of studies suggest a
threshold approach might be more suitable.64e71 This research
project aims to contribute to this discussion.Sex Med 2020;-:1e12
Sexual Function in PCOS: A Study Protocol 3Differences in androgen receptor (AR) activity and hence
sensitivity to androgens might complicate the relationship be-
tween androgens and sexual function. Functional studies have
demonstrated that an inverse relationship exists between the
CAG repeat length and receptor expression impacting on the
strength of the androgen action and sensitivity to sex hor-
mones.72 Several authors have studied the potential association
between shorter CAG repeats and a high testosterone level in
PCOS as well as the general population, with conflicting
results.73e79 Ethnicity, small sample sizes, and different defini-
tions of PCOS and hyperandrogenism may underlie these
inconsistent results. Moreover, a non-linear relationship between
CAG length and AR activity has been suggested.80 Therefore, it
is plausible that CAG repeat length variants are involved in the
pathogenesis of women with hyperandrogenism and influence
sexual function. For instance, a recent Danish population study
showed that lower numbers of CAG repeats were associated with
problems in reaching orgasm.81
The impact of OCP use on endocrine and sexual function has
been studied extensively in healthy women.82e92 OCPs are
known to decrease androgen and free testosterone
levels.56,57,90,92 Hypothetically, sexual function can be influ-
enced by this mechanism. Repeatedly, studies have shown that
some women report an OCP-related improvement in sexual
function, some a deterioration, whereas many report no change
in sexual function.82e86,88,89,93 In women with PCOS, OCPs
can restore androgen levels to normal, improving clinical
symptoms like acne and to a lesser extent hirsutism.7 Few studies
have assessed its influence on sexual function. Results varied from
improvement of sexual function, while normalizing androgen
levels,94 to deterioration of sexual desire.95
In addition to differences in androgen sensitivity, in women
with PCOS neuronal circuits in the brain might be impaired due
to hyperandrogenism, resulting in a disruption of sex steroid
feedback mechanisms.96,97 Following this line of reasoning, we
will assess androgen levels, CAG repeat length, and actual genital
response to sexual stimuli (vibrotactile, film fantasy) in a psy-
chophysiological laboratory setting while taking into account the
other factors presented here. As a result, we hope to be able to
shed more light on the role of androgen levels in sexual
responsiveness of women with PCOS.
Women with PCOS report significantly less sexual arousal and
lubrication compared to normal controls,38 but it is unknown
whether women with PCOS actually show abnormal physio-
logical sexual responses. A pilot study concerning the effect of
circulating androgen levels found no significant differences in
clitoral vascularization in non-aroused women with PCOS in
comparison with control women,98 but nothing is known about
the genital response to sexual stimulation. There are indications
that androgens influence sexual response to sexual fantasies and
genital tactile stimulation, whereas the effect of visual stimuli is
less influenced by androgen levels.99,100 To objectively assess
genital response to sexual stimuli and its contribution to sexualSex Med 2020;-:1e12function, psychophysiological measurements with vaginal pulse
amplitude (VPA) are required.
The primary aim of this study is to assess differences between
women with PCOS and control women in the following sexual
outcome measures: Female Sexual Function Index (FSFI), Fe-
male Sexual Distress Scale-Revised (FSDS-R), Sexual Desire
Inventory (SDI), and genital and subjective sexual responsiveness
to sexual stimuli measured with VPA. Secondary aims are to
investigate differences in these outcome measures between OCP
users and non-users in interaction with PCOS status in an
exploratory way, and to assess factors that may mediate the
relationship between PCOS status and sexual outcome measures.
We will assess the following mediators: testosterone, free
androgen levels, OCP use, sensitivity to androgens (using CAG
repeat length), body mass index (BMI), body image, mental
health, and self-esteem.
We expect to find lower sexual function and higher sexual
distress in the PCOS group compared with the control group.38
Further, we expect to find stronger genital and self-reported
sexual responsiveness in women with higher androgen levels in
both the fantasy and vibrotactile stimulation conditions but not
with visual sexual stimuli.99,100
Following the threshold model,64e71 we do not predict a
linear relationship between VPA response and androgen levels
(free testosterone and total testosterone). We do expect women
with the lowest bioavailable androgen levels (control women
using OCPs) to show lower levels of VPA response than women
in the upper 3 quartiles of bioavailable androgen levels (women
with PCOS not using OCPs).
We hypothesize that women with PCOS will score lower on
various psychosocial and mental health measures compared with
control women.17 We expect these scores to be associated with
impaired scores on sexual function questionnaires.34e37
We have no specific expectation for the relationship between
sexual outcomes and CAG repeat length in both women with
and without PCOS. CAG repeat length will be measured to
exploratively assess individual differences in sensitivity to an-
drogens and the relationship with PCOS status and other
variables.METHODS
Design
This study is a non-randomized observational prospective case
control study in a multicenter setting assessing the difference in
sexual function between women with and without PCOS.
Additionally, we examine the effect of OCP use resulting in a
22 design. The duration of the study will be 4 years. 3 Dutch
academic medical centers will participate in this study: Erasmus
Medical Center Rotterdam, Leiden University Medical Center
(LUMC), and Amsterdam University Medical Center (AMC).
Independent variables are PCOS status and OCP use. The
4 Pastoor et aldependent variables are sexual function as assessed with ques-
tionnaires and genital and self-reported sexual arousal in a lab-
oratory setting.
Ethical approval was awarded by the Ethics Committee of
Erasmus Medical Center, Rotterdam, The Netherlands (MEC
2016-216, NL55484.078.16). Local ethical approval was awar-
ded by the Ethics Committees of LUMC (P16.299) and AMC
(2016_182/NL55484.078.16).Participant Recruitment and Selection
Women who have been diagnosed with PCOS at the outpa-
tient clinic of the Erasmus University Medical Center will be
asked to participate in this study. Also, Dutch patient societies
will be requested to advertise for our study. PCOS will be
diagnosed according to the Rotterdam criteria.
An age-matched control group of healthy women will be
recruited through advertisements in local newspapers, social
media, or flyers at the outpatient gynecological clinics of Erasmus
University Medical Center, LUMC, and AMC. Control women
will also be recruited through the pool of volunteers available at
LUMC. In the control group, women with PCOS will be
excluded. In case PCOS is diagnosed, data will be used in the
PCOS arm.
Inclusion criteria for participation are healthy women with a
diagnosis of PCOS, healthy women without another diagnosis
concerning the menstrual cycle, women aged between 18 and
40 years, and those with a stable heterosexual relationship for at
least 6 months. Due to the nature of the erotic film material and
the sexuality questionnaires, only heterosexual women are
eligible.
Medical screening involves endocrine screening, assessment of
BMI, a menstrual cycle history, a modified Ferriman-Gallwey
score, and a transvaginal ultrasound in order to assess the
ovarian morphology, antral follicle counts, and ovarian volumes
of both ovaries. Total endometrial thickness will also be recorded
as well as uterine sizes. The diagnosis of PCOS or of a normal
menstrual cycle will be made after a standardized initial exami-
nation is performed between 07:45 and 10:00 AM after an
overnight fast in the early follicular phase of the menstrual cycle
(third to fifth day of menses when no hormonal contraception is
used) in case of a regular menstrual cycle. In case of a cycle ir-
regularity, the examination will be performed on a random cycle
day. In case of OCP use, screening will be on the eighth day of a
new cycle after 7 days of not using OCPs. Endocrine features
combined with medical screening will determine the diagnosis.
We will recruit women with PCOS and healthy women both
either not using hormonal contraceptives (for at least 3 months
prior to the start of their participation in this research project) or
using OCPs for at least 3 months. We aim to include a similar
number of women using OCPs as women not on OCPs in both
the PCOS group and the control group.Exclusion criteria for participation are psychiatric disorder,
pregnancy or lactation, having undergone a hysterectomy (all
indications), oophorectomy, or prolapse surgery, current or
recent use of medications that are known to influence sexual
response with the exception of OCPs, and (previous) medical
disorders (other than PCOS) that are known to influence sexual
response.Sample Size Calculation
Considering the 5 primary outcome variables, we will apply
Bonferroni correction, a 2-sided alpha of 0.01, and a power of
0.80.
ter Kuile et al reported differences between women with
(N ¼ 234) and without sexual problems (N ¼ 108) on the FSFI
and FSDS with effect sizes of, respectively, d ¼ 1.9 and 2.3.119
For an effect size of d ¼ 1.9, eight cases in each group are
needed, and for an effect size of d ¼ 2.3, 6 cases are required.
No data on the SDI are available for differences in women
with PCOS. Strizzi et al121 reported an SDI of 38.1 (±16.56) in
a sample of 29 women with a traumatic brain injury and a value
of 49.59 (±21.09) in 29 normal controls, a difference of
d ¼ 0.60, suggesting that N ¼ 67 cases for each group is
required.
No data on VPA response in women with PCOS are avail-
able. However, there are VPA data available related to differ-
ences in premenopausal (N ¼ 56) and postmenopausal
(N ¼ 32) women as reported by Both et al.122 In this study the
difference in VPA response between premenopausal and post-
menopausal women was reported as an F-value of 9.09 (degrees
of freedom 1;84) corresponding to an effect size of n2 ¼ 0.10
of d ¼ 0.66. For such an effect 53 cases are needed in each
group.
The largest sample needed is for the SDI; hence, we need 134
participants. Anticipating a small dropout of 10% we need 150
participants totally.Materials and Measures
Blood Samples and Endocrine Screening
Peripheral venous blood samples to assess androgen levels will
be collected in all participants: total testosterone, SHBG, and
calculated free androgen index: testosterone  100/SHBG.
Additionally, all of the following will be assessed in all partici-
pants: estradiol, progesterone, luteinizing hormone, follicle
stimulating hormone, androstedione, dehydroepiandrosterone,
dehydroepiandrosterone sulfate, thyroid stimulating hormone,
prolactin, lipids, and fasting glucose and insulin. Plasma will be
stored at 80C. Samples will be analyzed using liquid chro-
matography mass spectrometry.
We will determine the number of CAG repeats in 4 different
ways: the number of CAG repeats in the allele containing theSex Med 2020;-:1e12
Sexual Function in PCOS: A Study Protocol 5fewest CAG repeats (short allele), the number of CAG repeats in
the allele containing the most CAG repeats (long allele), the
mean number of CAG repeats (biallelic mean), and the number
of CAG repeats in the active X chromosome based on X-inac-
tivation analysis (X-weighted biallelic mean). The CAG repeat
region in the first exon of the AR gene on the X chromosome will
be amplified from genomic DNA with a polymerase chain
reaction-based assay. Another possibility is to define single
nucleotide polymorphisms that will detect the different variable
number tandem repeat alleles and perform a less cumbersome
Global Screening Array. We probably will take the latter
approach to determine AR sensitivity.
The medical and endocrine screening as well as the DNA
analysis for all participants will be done at 1 laboratory at Eras-
mus University Medical Center, to ensure compatibility of data.Questionnaires
We will measure the following variables as primary outcomes
(Table 1): sexual function with the FSFI total score (19 items,
cutoff <26.55 indicative of sexual dysfunction)101; sexual
distress with the FSDS-R total score (13 items, score >15
indicative of distress)101; and solitary and dyadic sexual desire
with the SDI (14 items, 2 scales [solitary desire scale and dyadic
desire scale] and total scale; a higher score reflects higher levels of
sexual desire)102 as an additional measure of sexual desire due to
limitations in the desire scale of the FSFI.103
Other variables will be used as mediators (Table 1): sexual
self-esteem measured by Sexual Esteem Scale (10 items, a
higher total score indicates more sexual self-esteem)49,104;
general self-esteem with the Rosenberg Self-Esteem Scale total
score (10 items, a higher total score indicates more positive self-
esteem)105e107; body self-consciousness with the Body Image
Self-Consciousness Scale total score (15 items, a higher total
score indicates greater body self-consciousness)49,108; body
image with the Multidimensional Body-Self-Relations Ques-
tionnaire-Appearance Scales subscale (34 items, a higher total
score indicates a more positive body image)109; and mental
health with the Hospital Anxiety and Depression Scale total
score (14 items, a higher total score indicates mental
complaints).110,111
Some variables will be used as moderators (Table 1) as they are
not caused by the independent variable (PCOS status): a history
of sexual and physical abuse measured with Sexual and Physical
Abuse Questionnaire (7 items, yes/no answers)112; sexual exci-
tation and sexual inhibition propensity by Sexual Excitation/
Sexual Inhibition Inventory for Women (36 items, 2 subscales,
low Sexual Excitation Scale indicates low excitation, high Sexual
Inhibition Scale indicates high inhibition)113; relationship satis-
faction by Revised Dyadic Adjustment Scale total score (14
items, cutoff >48 for no distress).114,115Sex Med 2020;-:1e12All questionnaires have been validated and will be available in
a secure online environment.Sexual Response Assessment
Sexual response will be assessed in 4 erotic stimulus conditions:
3-minute self-induced erotic fantasy, 2-minute vibrotactile glans
clitoris stimulation, 5-minute erotic film, and 5-minute vibro-
tactile glans clitoris stimulation combined with an erotic
film.116,117 Both erotic films depict heterosexual foreplay and in-
tercourse. This film material has been previously used in studies
from the same research group.116,118e121 The short clips are taken
from women friendly erotic films which are known to be effective
in inducing a genital response. During the erotic fantasy condition,
participants will be asked to fantasize about a pleasant sexual sit-
uation. The vibrotactile glans clitoris stimulation is provided by a
small hands-off vibrator (2-cm diameter), attached to lycra panties.
Vibrotactile glans clitoris stimulation has been used previously in
studies on sexual response in women, and is known to elicit genital
and subjective sexual arousal.121 The intensity of the vibration can
be varied from very low1 to high.10 In the present study, high-
intensity vibration will be provided. Each stimulus period is pre-
ceded by a 5-minute neutral film period, and followed by a 10-
minute return-to-baseline interval during which participants will
work on a non-erotic concentration task and watch a neutral film.
A computer program coordinates the administration of the films
and the vibrotactile glans clitoris stimulation.
All participants will go through the different stimulus conditions
in the same order. Because sexual responses to erotic fantasy and
vibrotactile glans clitoris stimulation are expected to differ according
to androgen status, these 2 stimulus conditions are presentedfirst, to
avoid carry over from the visual stimuli that are known to be
androgen independent and to elicit higher genital responses than
fantasy and vibrotactile glans clitoris stimulation.61,99,100
Genital response will be measured using a vaginal photo-
plethysmograph assessing VPA.122e124 VPA is a sensitive, spe-
cific, and reliable measure of changes in vaginal vasocongestion in
response to sexual stimulation125 and has been used in earlier
studies in women with gynecological or neurological dis-
eases.120,126 The vaginal device is sized and shaped as a vaginal
tampon and can easily be inserted by the participant herself. It
contains a light source and an optical sensor. The light source
illuminates the capillary bed of the vaginal wall and the sensor
responds to the light backscattered by the vaginal wall and the
blood circulating within it. When the signal is connected to an
alternating current amplifier, VPA is measured, which reflects the
phasic changes in vaginal engorgement accompanying each
heartbeat, with larger amplitudes reflecting higher levels of
vaginal vasocongestion. Genital responses will be recorded
continuously during the experiment. VPA will be averaged for
the baseline condition and each erotic stimulus, and for each
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OCP ¼ oral contraceptive pill; PCOS ¼ polycystic ovary syndrome; VPA ¼
vaginal pulse amplitude.
6 Pastoor et alstimulus condition a change from the baseline score will be
calculated. Ratings of self-reported sexual arousal and affect will
be collected after each erotic stimulus. Participants will be asked
to assess on a 7-point Likert scale their strongest feeling of sexual
arousal.127,128Procedure
Women with PCOS and healthy control women will be asked
to participate in the study and will be given an informational
brochure. A week later a coordinator will contact each woman
by telephone to give further information about the study, to
answer questions, to check eligibility, and to determine partici-
pation. If a woman wants to participate, written informed
consent will have to be provided. Only then peripheral venous
blood samples will be collected (if not already recently done).
After this the participant will receive an e-mail with a link to the
web-based questionnaires. The questionnaires will also be
available on paper if necessary. Within 2 weeks an appointment
will be made to conduct the sexual response assessment (VPA)
(Figure 1).
The sexual response assessment will be performed at the psy-
chophysiological laboratory of LUMC or AMC. All women will be
tested individually by a trained female experimenter. The experi-
menter will explain the details of the experimental procedure and
the purpose of the experiment. The experimenter will then leave the
room to allow the participant to apply the vibrator and insert the
vaginal probe privately. The participant is allowed to put on herclothes again after applying the vibrator and inserting the vaginal
probe. During the experimental procedure the experimenter will be
in an adjacent room; contact will be possible by using an intercom.
All further instructions, the stimuli, and the questionnaire about
self-reported sexual arousal and affect will be presented on amonitor
in the participant's room. At the end of the experiment, an exit
interview questionnaire will be administered. Participants will be
asked about their reactions to the experimental procedure and the
use of the genital device (Figure 1).Statistical Analysis
Normality of the outcome data will be determined with
Shapiro-Wilk tests. In case of non-normality, an appropriate
transformation will be performed. The difference between
women with PCOS and controls will be analyzed with separate
multilevel regression analyses for each of the 5 outcomes. Inde-
pendent variables will be PCOS (vs controls), fantasy (vs film),
and vibration and interactions of PCOS with fantasy and vi-
bration. P values of .01 will be considered significant.
For the differences between women with PCOS and controls,
and women using OCPs and women not using OCPs, OCP use
and interactions with PCOS, fantasy, and vibration will be added
to the multilevel analyses.
Mediation regression analyses, as described by Mathieu and
Tailor,129 will be extended to multilevel mediation regression
analyses to estimate the mediating effects of steroid hormone
levels, and sexual and psychosocial parameters in the relation of
PCOS/OCP use on the 5 sexual outcome measures.
We will apply regression curve estimation with sexual function
as the dependent variable and CAG repeat length and several
functions of the CAG repeat length as independent variables to
analyze a possible non-linear relation.DISCUSSION
An important strength of this research project is the assess-
ment of biological (eg, VPA, BMI, CAG repeats, extensive
endocrine measurement) as well as psychosocial (eg, Hospital
Anxiety and Depression Scale, Revised Dyadic Adjustment
Scale) and sexual variables (eg, FSFI, FSDS-R) in women with
and without PCOS. In so doing, we expect to be able to test a
number of specific hypotheses with respect to sexual function
in women with PCOS as well as to exploratively investigate
associations between biopsychosocial variables and sexual
function that may generate specific hypotheses for future
studies.
Another strength of this study is the large number of partic-
ipants including an age-matched control group. This large
number of participants makes it possible to stratify the study
according to PCOS phenotype or OCP use. This may help to
further elucidate the role of OCP use and endocrine factors in












- Medical & endocrine screening
- Questionnaires
- VPA measurement (figure 1b)
Results medical & endocrine screening
- Inclusion: PCOS confirmed
- Exclusion: PCOS not confirmed
Healthy 
control
- Medical & endocrine screening
- Questionnaires
- VPA measurement (figure 1b)
Results medical & endocrine screening
- Inclusion: Healthy control confirmed 
OR PCOS diagnosis -> referral to PCOS group
- Exclusion: Healthy control not confirmed
1a. non-erotic baseline movie, 1b. subjective arousal / affect ratings
3. non-erotic concentration task 
2a. engaging in erotic fantasy, 2b. subjective arousal / affect ratings  
4. non-erotic back-to-baseline movie 
5a. vibrotactile clitoral stimulation, 5b. subjective arousal / affect ratings   
7. non-erotic back-to-baseline movie 
6. non-erotic concentration task
8a. erotic movie, 8b. subjective arousal / affect ratings  
9. non-erotic concentration task
11a. erotic movie + vibrotactile clitoral stimulation, 11b. subjective arousal / affect ratings  
12. level of lubrication rating 
10. non-erotic back-to-baseline movie 
A
B
Figure 1. (A) Flowchart design protocol assessments. (B) Order of tasks and stimuli during VPA measurement. PCOS ¼ polycystic ovary
syndrome; VPA ¼ vaginal pulse amplitude.
Sexual Function in PCOS: A Study Protocol 7We encountered problems while including women with
PCOS. We expected to include participants mainly through the
Erasmus University Medical Center since the hospital has a
PCOS expertise center and can therefore access a large popu-
lation of women with PCOS. As it turned out, only few women
recruited through this center were interested in or eligible to
participate in this study. Recruitment through patient support
groups worked very well and is ongoing. In hindsight, the
difficulties in recruiting participants at the PCOS expertise
center may be related to a large proportion of that patient
population seeking medical treatment in order to become
pregnant.
Also, the measurement of genital and subjective sexual
response during exposure to sexual stimuli may have been a
reason for non-participation. However, this did not complicateSex Med 2020;-:1e12recruitment of control women and of women with PCOS
recruited through patient support groups.
All participants were carefully recruited and assessed according
to the study design.
Trial registration was retrospective but was done during the
recruitment phase. Since this is not a clinical trial, registration
was not required. We nevertheless consider trial registration and
protocol publication of a cross sectional study such as the present
one to be important, so as to enhance transparency about the
design and hypotheses.
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